Skip to content

The effects of transcutaneous electrical acupoint stimulation combined with dolasetron for reducing incidence rate of postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery

The effects of transcutaneous electrical acupoint stimulation combined with dolasetron for reducing incidence rate of postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095934
Enrollment
Unknown
Registered
2025-01-15
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative nausea and vomiting

Interventions

group A:dolasetron
group B:dolasetron+dexamethasone
group C:transcutaneous electrical acupoint stimulation+dolasetron
group D: transcutaneous electrical acupoint stimulation+dolasetron+dexamethasone

Sponsors

Qingdao Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing gynecological laparoscopic surgery 2. ASA grade: ?~?; 3. Age: 18-65 years; 4. Patients were informed of this study and signed informed consent to voluntarily cooperate with this study 5. Patients who are not allergy to narcotic drugs or drugs used in the study; 6. All included patients had not take any antiemetic medication in the 7 days prior to surgery: 7. Patients are informed about this study and sign the informed consent form, and voluntarily cooperate with this study; 8. Patients with no history of allergic reaction to narcotic drugs and drugs used in the study.

Exclusion criteria

Exclusion criteria: 1. Allergy to metal, or have pacemakers,metal implants, etc; 2. Skin damaged at the wrists; 3. Mental disorder or cognitive impairment, can't communicate normally; 4. History of major trauma or surgery 5. History of chemotherapy within 4 weeks or radiotherapy within 8 weeks; 6. Have used steroid hormone or other antiemetic drugs within 1 week; 7. A history of opioid or alcohol addiction; 8. Liver and kidney dysfunction; 9. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
frequency and degree of postoperative nausea and vomiting ;use of metoclopramide for antiemesis after sugery;The combined use of drugs during and after operation;Occurrence of dizziness, headache, hypertension and hypotension after operation;

Secondary

MeasureTime frame
Operation time, infusion volume and blood loss;Occurrence of hypotension and hypertension during operation;

Countries

China

Contacts

Public ContactLiu Junchao

Qingdao Municipal Hospital

junchaoliu1205@163.com+86 136 5532 1632

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026